Is diabetes a causal agent for colorectal cancer? pathophysiological and molecular mechanisms

World Journal of Gastroenterology

Volumn 17, Issue 4, 2011, Pages 444-448

  Giouleme, Olga ^a   Diamantidis, Michael D ^a   Katsaros, Marios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Colorectal cancer; Diabetes mellitus; Molecular oncogenic pathways; Screening

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN; SOMATOMEDIN C;

ASCENDING COLON; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC DRUG ADMINISTRATION; COLONOSCOPY; COLORECTAL CANCER; DESCENDING COLON; DIABETIC PATIENT; DIET; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG USE; GASTROINTESTINAL DISEASE; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN TREATMENT; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRACTICE GUIDELINE; PREDICTION; REVIEW; SEDENTARY LIFESTYLE; SIGNAL TRANSDUCTION;

EID: 79955932544     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i4.444     Document Type: Review

References (36)

1. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-378
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
3. Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Gale EA, Patterson CC, Keen H. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005; 92: 2070-2075
4. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365
5. Ogunleye AA, Ogston SA, Morris AD, Evans JM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009; 101: 1199-1201
6. Smith CJ, McKay GA, Fisher M. Diabetes, colorectal cancer and cyclooxygenase 2 inhibition. Int J Clin Pract 2008; 62: 810-815
7. Zendehdel K, Nyrén O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95: 1797-1800
8. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ 3rd, Sellers TA, Cerhan JR. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006; 101: 1872-1879
9. Oh SW, Kim YH, Choi YS, Chang DK, Son HJ, Rhee PL, Kim JJ, Rhee JC, Yun SH, Lee WY, Chun HK, Kim DH, Shim SG. The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancer. Dis Colon Rectum 2008; 51: 56-61
10. Ren X, Zhang X, Zhang X, Gu W, Chen K, Le Y, Lai M, Zhu Y. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 2009; 123: 540-544
11. Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am J Gastroenterol 2006; 101: 1866-1871
12. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 587-594
13. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 2008; 51: 593-597
14. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-1050
15. Nagel JM, Göke B. [Colorectal carcinoma screening in patients with type 2 diabetes mellitus]. Z Gastroenterol 2006; 44: 1153-1165
16. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 2008; 53: 2486-2494
17. Caudle AS, Kim HJ, Tepper JE, O'Neil BH, Lange LA, Goldberg RM, Bernard SA, Calvo BF, Meyers MO. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol 2008; 15: 1931-1936
18. Jullumstrø E, Kollind M, Lydersen S, Edna TH. Diabetes mellitus and outcomes of colorectal cancer. Acta Oncol 2009; 48: 361-367
19. Berster JM, Göke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 2008; 114: 84-98
20. Björk J, Nilsson J, Hultcrantz R, Johansson C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol 1993; 28: 879-884
21. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992; 8: 229-257
22. Sun J, Jin T. Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal 2008; 20: 219-229
23. Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 2008; 149: 2341-2351
24. Sun J, Khalid S, Rozakis-Adcock M, Fantus IG, Jin T. P-21- activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine. Oncogene 2009; 28: 3132-3144
25. Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, Potter JD, Levin TR, Samowitz W. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 2006; 17: 239-249
26. Jin T. Why diabetes patients are more prone to the development of colon cancer? Med Hypotheses 2008; 71: 241-244
27. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007; 86: s836-s842
28. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-788
29. Phelip JM, Roblin X. Type 2 diabetes mellitus and colorectal cancer risk: is homocysteine the missing link? Am J Gastroenterol 2007; 102: 466-467
30. Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested casecontrol study in veterans with diabetes. Am J Gastroenterol 2009; 104: 1241-1248
31. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99: 32-40
32. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133: 393-402
33. Ahnen DJ, Byers T. Editorial: Colorectal cancer and statins: reflections from the end of the road. Am J Gastroenterol 2009; 104: 3024-3026
34. Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009; 104: 3015-3023
35. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192
36. Malicki S, Winiarski M, Matlok M, Kostarczyk W, Guzdek A, Konturek PC. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol 2009; 60: 141-146